Dignify Therapeutics Advances into Clinic with FDA Clearance of IND for DTI-117 in Neurogenic Bowel Dysfunction
Dignify Therapeutics received FDA clearance of an IND for DTI-117, moving its neurogenic bowel dysfunction program into the clinic.
Dignify Therapeutics
Private
Neurological drug and medical device company developing “on demand” therapies that restore bowel and bladder control for people with neurological disorders.
Company Info
Sector:Neuroscience / Urology Therapeutics
Headquarters:Research Triangle Park, North Carolina, United States
Founded:2015
Website:dignifytherapeutics.com/